3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
85
Breast Neoplasms
62
Prostatic Neoplasms
44
Lung Neoplasms
35
Multiple Myeloma
34
Neoplasms
27
Colorectal Neoplasms
23
Parkinson Disease 4, Autosomal Dominant Lewy Body
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Neoplasm Metastasis
20
Ovarian Neoplasms
18
Carcinoma, Renal Cell
17
Urinary Bladder Neoplasms
13
Small Cell Lung Carcinoma
13
Pancreatic Neoplasms
13
Endometrial Neoplasms
13
Myasthenia Gravis
12
Leukemia, Myeloid, Acute
12
Squamous Cell Carcinoma of Head and Neck
11
Recurrence
11
Nasopharyngeal Carcinoma
11
Triple Negative Breast Neoplasms
10
Stomach Neoplasms
10
Non-Muscle Invasive Bladder Neoplasms
10
Lymphoma, Follicular
10
Lymphoma, Non-Hodgkin
9
Fallopian Tube Neoplasms
9
Melanoma
8
Colonic Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
7
Interventions
palbociclib
1
lenvatinib
1
cabozantinib
1
belzutifan
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
von Hippel-Lindau Disease
×
30 days
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled